메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
류민희 (울산대학교)
저널정보
대한종양외과학회 KOREAN JOURNAL OF CLINICAL ONCOLOGY Korean Journal of Clinical Oncology 제10권 제1호
발행연도
2014.6
수록면
1 - 5 (5page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
In localized resectable stage II or III gastric cancer, D2 dissection has been accepted as the standard surgical method worldwide. The Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer and Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer phase III trials have demonstrated that systemic adjuvant chemotherapy can significantly improve recurrence-free survival (RFS) and overall survival (OS) after D2 dissection with absolute survival benefit of 10% to 15% compared with surgery alone. Addition of radiation or intensification of adjuvant chemotherapy has been tried in localized resectable gastric cancer for further improvements of RFS and OS as well. However, addition of radiation after D2 dissection was proven to play no or only a minimal role at its best in reduction of loco-regional recurrences as well as distant metastases. The results of recent large-scale adjuvant trials suggest that more intensified adjuvant treatment including multiple chemotherapeutic agents would not likely induce a better result. For this reason, addition of neoadjuvant chemotherapy to current standard of care may be the only plausible strategy to improve long-term outcomes in localized resectable gastric cancer, and clinical trials of neoadjuvant chemotherapy are now ongoing in gastric cancer.

목차

서론
본론
결론
REFERENCES

참고문헌 (0)

참고문헌 신청

이 논문의 저자 정보

이 논문과 함께 이용한 논문

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-ECN-0101-2015-510-002475241